Table 1.
Resistance test results on the three patients with protease mutations additionally identified by NGS.
| Subject | Drugs received before PIVOT | Regimen during PIVOTa | Weeks since randomisation | Viral load (copies/ml) | Protease mutations by Sanger sequencingb | Protease mutations by NGSb | Predicted PI resistancec |
|---|---|---|---|---|---|---|---|
| A | TDF, FTC, EFV | ATV/r | 48 | 23,400 | I50I/L, K20K/T | ND | ATV(H) |
| 57 | 3300 | K20K/T | K20T (13%; 99,917), G73D (10%; 76,126) | ATV(PL),FPV(PL),SQV(L)d | |||
| 61 | 2400 | None | ND | ||||
| B | ZDV, TDF, 3TC, FTC, EFV | DRV/r | 48 | 35,431 | ND | I54T (2%; 112,532) | ATV (L), LPV(L) |
| 52 | 17,700 | None | ND | ||||
| C | TDF, FTC, LPV/r | LPV/r | 41 | 10,700 | None | L89V (5%; 98,051) | FPV(PL) |
ND = not done.
a
All three subjects remained on same regimens from randomisation to date of resistance test samples.
b
Major or accessory mutations according to Stanford HIVdb Version 8.1.1. I50L is major mutation; all other listed mutations are accessory. Values in parentheses are frequency of mutation; depth of read at that position.
c
Predicted by Stanford HIVdb Version 8.1.1, based on consensus NGS sequence (preferentially) or Sanger sequence. PL = potential low level, L = low level, H = high.
d
Predicted to be susceptible to all drugs by mutations detected by Sanger sequencing.